Nhà máy Stada
Cardiovascular Agents

Nifedipin T20 STADA® retard

Packaging: Box of 10 blisters x 10 tablets.

Composition: Each retard film-coated tablet contains:

Nifedipine               20 mg

Excipients q.s          1 tablet

Shelf - Life:

  48 months from the date of manufacturing.

  • Indications
  • Contraindications
  • Adverse reactions

  • For the treatment of coronary heart disease (conditions characterised by inadequate oxygen supply to the heart muscle):
  • Vasospastic angina pectoris (Prinzmetal's angina, variant angina).
  • Chronic stable angina pectoris (effort angina).
  • For the treatment of essential hypertension (high blood pressure).

Nifedipine should not be used in cardiovascular shock, with narrowing of the aorta (higher-grade aortic stenosis), with known hypersensitivity to nifedipine, with unstable angina pectoris and acute myocardial infarction (within the first 4 weeks), in patients with very low blood pressure (severe hypotension with a systolic blood pressure under 90 mmHg), in cases of manifest heart failure.

  • Headache and reddening of the face (flushing) and sensation of heat may be experienced.
  • There have been occasional reports of skin reactions, tingling sensations in the arms and legs (paraesthesias), dizziness and fatigue, nausea, constipation and diarrhoea.
  • There have also been occasional reports of blood pressure reduction below normal (hypotensive circulatory response), palpitations and a rise in pulse rate (tachycardia) as well as of leg oedemas (fluid accumulation in the lower legs) due to widening of blood vessels.
  • There have been reports of blood formation changes, such as anaemia, leucopenia, thrombocytopenia and thrombocytopenic purpura, being associated with nifedipine therapy.
  • Prolonged treatment has, on extremely rare occasions, been associated with gum alterations (gingival hyperplasia), which resolved completely upon discontinuation.
  • There have been isolated reports of impaired liver function (intrahepatic cholestasis, transaminase elevations) and allergic hepatitis.
  • There have been very rare reports of elevated blood glucose concentrations in serum (hyperglycaemia). This should be borne in mind in patients with diabetes mellitus in particular.
  • There have been isolated reports of breast enlargement in men (gynaecomastia), resolving upon discontinuation of the drug.
  • Abrupt withdrawal of nifedipine in patients with high blood pressure (hypertension) or coronary heart disease may precipitate a hypertensive crisis or reduce the blood flow to the heart muscle (myocardial ischaemia) as a consequence of what is known as "rebound".
  • Especially at the start of therapy, patients may occasionally experience anginal attacks or patients with pre-existing angina pectoris may occasionally experience an increase in the frequency, duration and severity of anginal attacks. There have been isolated reports of myocardial infarction.
  • Caution must be exercised in dialysis patients with severe high blood pressure (malignant hypertension) and irreversible kidney failure with reduced circulating blood volume (hypovolaemia) because they may experience a significant blood pressure fall through widening of blood vessels (vasodilatation).


  • Treatment should be individualized to reflect disease severity and patient responsiveness.
  • Dependent on the respective clinical picture, stabilization with reference to the final dose should be made slowly. Patients with limited liver function should be carefully controlled. In some cases, a reduction of dose may be necessary.

The following dosage is recommended for adults:

Coronary heart disease:

  • Vasospastic angina pectoris (Prinzmetal's angina, variant angina): 1 tablet (20 mg of nifedipine) twice daily.
  • Chronic stable angina pectoris (effort angina): 1 tablet (20 mg of nifedipine) twice daily.
  • The recommended dosage can be increased to 2 tablets (40 mg of nifedipine) twice daily.
  • Essential hypertension (high blood pressure): 1 tablet (20 mg of nifedipine) twice daily.
  • The recommended dosage can be increased to 2 tablets (40 mg of nifedipine) twice daily.

Method of administration and duration of therapy:

  • The drug is usually swallowed whole after meals with a sufficient amount of liquid (about a glass of water). Concurrent food intake will delay absorption. There should be an interval of at least 4 hours between any two recommended doses.
  • Continue treatment at the dosage prescribed by the doctor. In no event must a patient takes a double dose next time to make up for the missed dose.
  • Nifedipine, especially when used in high doses, should be tapered off gradually to avoid an increase in anginal attacks. Inform the doctor if the patient wants to interrupt or stop treatment prematurely.
  • The duration of therapy will be decided by the treating doctor.

Contact us

FACTORY 1: K63/1 Nguyen Thi Soc St., Xuan Thoi Dong, Hoc Mon, HCMC
Tel: +84 28 3718 2141 - Fax: +84 28 3718 2140

FACTORY 2: 40 Tu Do Avenue, VietNam-Singapore Industrial Park, Binh Duong
Tel: +84 274 376 7470 - Fax: +84 274 376 7469
Email : stada@stada.com.vn
Website: www.stada.com.vn

Visitors Counter